New CAR T-Cell therapy targets hidden leukemia cells to prevent relapse
NCT ID NCT06144606
First seen Nov 16, 2025 · Last updated Apr 29, 2026 · Updated 22 times
Summary
This study tests a CAR T-cell therapy called KTE-X19 in adults with B-cell acute lymphoblastic leukemia (B-ALL) who are in remission but still have tiny amounts of cancer cells (minimal residual disease, or MRD). The goal is to see if the treatment can eliminate these hidden cells and prevent the cancer from coming back. About 60 participants will receive a single infusion of their own genetically modified immune cells. The main measure of success is how long people stay relapse-free after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.